A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation

Abstract

Methods: The study was approved by the Institutional Review Board. Eligibility included > 1 cm tumor and germline BRCA mutation. HER2+ tumors were excluded. Pts underwent a pre-treatment biopsy, 2 months of talazoparib, off-study core biopsy, anthracycline and taxane-based chemotherapy +/-carboplatin, followed by surgery. Ultrasound tumor evaluations by dedicated breast ultrasonographers were obtained at baseline, 1 and 2 months. Success was defined if 20 patients could be accrued within 2 years and < 33% experienced a grade 4 toxicity. Tumor volume = (length x width x height x π)/6.